Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 86

1.

Dynamic use of B-type natriuretic peptide-guided acute coronary syndrome therapy.

Dong SY, Dong MS, Chen ZH, Sun J, Yang X, Zeng Q.

Am J Med Sci. 2014 Oct;348(4):283-7. doi: 10.1097/MAJ.0000000000000245.

PMID:
24762749
2.

A combination of increased Rho kinase activity and N-terminal pro-B-type natriuretic peptide predicts worse cardiovascular outcome in patients with acute coronary syndrome.

Dong M, Liao JK, Yan B, Li R, Zhang M, Yu CM.

Int J Cardiol. 2013 Sep 10;167(6):2813-9. doi: 10.1016/j.ijcard.2012.07.007. Epub 2012 Aug 24.

3.
4.

Long-term results of intensified, N-terminal-pro-B-type natriuretic peptide-guided versus symptom-guided treatment in elderly patients with heart failure: five-year follow-up from TIME-CHF.

Sanders-van Wijk S, Maeder MT, Nietlispach F, Rickli H, Estlinbaum W, Erne P, Rickenbacher P, Peter M, Pfisterer MP, Brunner-La Rocca HP; TIME-CHF Investigators.

Circ Heart Fail. 2014 Jan;7(1):131-9. doi: 10.1161/CIRCHEARTFAILURE.113.000527. Epub 2013 Dec 18.

6.

Prognostic value of biomarkers during and after non-ST-segment elevation acute coronary syndrome.

Eggers KM, Lagerqvist B, Venge P, Wallentin L, Lindahl B.

J Am Coll Cardiol. 2009 Jul 21;54(4):357-64. doi: 10.1016/j.jacc.2009.03.056.

7.

NT-proBNP levels in patients with non-ST-segment elevation acute coronary syndrome.

Castro LR, Alencar MC, Barbosa MM, Nunes Mdo C, Cardoso JR, Ribeiro AL.

Arq Bras Cardiol. 2011 Dec;97(6):456-61. Epub 2011 Oct 27. English, Portuguese.

8.

Sensitive troponin assays and N-terminal pro-B-type natriuretic peptide in acute coronary syndrome: prediction of significant coronary lesions and long-term prognosis.

Gravning J, Smedsrud MK, Omland T, Eek C, Skulstad H, Aaberge L, Bendz B, Kjekshus J, Mørkrid L, Edvardsen T.

Am Heart J. 2013 May;165(5):716-24. doi: 10.1016/j.ahj.2013.02.008. Epub 2013 Mar 26.

PMID:
23622908
9.

N-terminal B-type natriuretic peptide assessment provides incremental prognostic information in patients with acute coronary syndromes and normal troponin T values upon admission.

Weber M, Bazzino O, Navarro Estrada JL, Fuselli JJ, Botto F, Perez de Arenaza D, Möllmann H, Nef HN, Elsässer A, Hamm CW.

J Am Coll Cardiol. 2008 Mar 25;51(12):1188-95. doi: 10.1016/j.jacc.2007.11.054.

10.

A multimarker risk stratification approach to non-ST elevation acute coronary syndrome: implications of troponin T, CRP, NT pro-BNP and fibrin D-dimer levels.

Tello-Montoliu A, Marín F, Roldán V, Mainar L, López MT, Sogorb F, Vicente V, Lip GY.

J Intern Med. 2007 Dec;262(6):651-8. Epub 2007 Nov 7.

11.

NT-proBNP for prognostic and diagnostic evaluation in patients with acute coronary syndromes.

Zdravkovic V, Mladenovic V, Colic M, Bankovic D, Lazic Z, Petrovic M, Simic I, Knezevic S, Pantovic S, Djukic A, Zdravkovic N.

Kardiol Pol. 2013;71(5):472-9. doi: 10.5603/KP.2013.0093.

13.

Evaluation of B-type natriuretic peptide for risk assessment in unstable angina/non-ST-elevation myocardial infarction: B-type natriuretic peptide and prognosis in TACTICS-TIMI 18.

Morrow DA, de Lemos JA, Sabatine MS, Murphy SA, Demopoulos LA, DiBattiste PM, McCabe CH, Gibson CM, Cannon CP, Braunwald E.

J Am Coll Cardiol. 2003 Apr 16;41(8):1264-72. Erratum in: J Am Coll Cardiol. 2003 May 21;41(10):1852.

14.

Prognostic value of N-terminal-pro-brain natriuretic peptide measurements in patients with acute coronary syndromes.

Ranjith N, Pegoraro RJ, Naidoo DP, Esterhuizen TM.

Cardiovasc J S Afr. 2006 Mar-Apr;17(2):60-6.

15.

N-terminal pro-B-type natriuretic peptide in risk stratification after acute myocardial infarction in patients on long-term beta-adrenergic receptor blocker therapy.

Jonsson G, Abdelnoor M, Landaas S, Muller C, Kjeldsen SE, Os I, Westheim A.

Cardiology. 2006;106(2):102-8. Epub 2006 Apr 21.

PMID:
16636540
16.

N-terminal pro-B-type natriuretic peptide levels for dynamic risk stratification of patients with acute coronary syndromes.

Heeschen C, Hamm CW, Mitrovic V, Lantelme NH, White HD; Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Investigators.

Circulation. 2004 Nov 16;110(20):3206-12. Epub 2004 Nov 8.

17.

N-terminal pro-brain natriuretic peptide for additional risk stratification in patients with non-ST-elevation acute coronary syndrome and an elevated troponin T: an Invasive versus Conservative Treatment in Unstable coronary Syndromes (ICTUS) substudy.

Windhausen F, Hirsch A, Sanders GT, Cornel J, Fischer J, van Straalen JP, Tijssen JG, Verheugt FW, de Winter RJ; Invasive versus Conservative Treatment in Unstable coronary Syndromes investigators.

Am Heart J. 2007 Apr;153(4):485-92.

PMID:
17383283
18.

Association between N-terminal pro-brain natriuretic peptide levels and contrast-induced nephropathy in patients undergoing percutaneous coronary intervention for acute coronary syndrome.

Kurtul A, Duran M, Yarlioglues M, Murat SN, Demircelik MB, Ergun G, Acikgoz SK, Sensoy B, Cetin M, Ornek E.

Clin Cardiol. 2014 Aug;37(8):485-92. doi: 10.1002/clc.22291. Epub 2014 May 7.

19.

The role of B-type natriuretic peptide testing in patients with acute coronary syndromes.

Linskey K, Lewandrowski K.

Minerva Cardioangiol. 2012 Apr;60(2):175-82.

PMID:
22495166
20.

Natriuretic peptides in heart failure and acute coronary syndrome.

Gaggin HK, Januzzi JL Jr.

Clin Lab Med. 2014 Mar;34(1):43-58, vi. doi: 10.1016/j.cll.2013.11.007. Epub 2014 Jan 14. Review.

PMID:
24507786

Supplemental Content

Support Center